Prostate Cancer

>

Latest News

Hypofractionation Noninferior to Conventional Radiotherapy for Low-Risk Prostate Cancer
Hypofractionation Noninferior to Conventional Radiotherapy for Low-Risk Prostate Cancer

July 8th 2024

Hypofractionated radiotherapy was noninferior to conventional radiotherapy in patients with low-risk prostate cancer.

PSMA Response May Indicate Better Metastasis Control in Oligometastatic CSPC
PSMA Response May Indicate Better Metastasis Control in Oligometastatic CSPC

July 7th 2024

Darolutamide Combination May Delay Disease Progression in Metastatic Hormone-Sensitive Prostate Cancer
Darolutamide Combination May Delay Disease Progression in Metastatic Hormone-Sensitive Prostate Cancer

June 11th 2024

Stopping Enzalutamide May Not Impact Quality of Life in Prostate Cancer Subset
Stopping Enzalutamide May Not Impact Quality of Life in Prostate Cancer Subset

June 7th 2024

Apalutamide Plus ADT May Not Negatively Impact QOL in Recurrent Prostate Cancer
Apalutamide Plus ADT May Not Negatively Impact QOL in Recurrent Prostate Cancer

June 4th 2024

Video Interviews

More News

© 2024 MJH Life Sciences

All rights reserved.